MyRadAgent
Home › Tools › Bosniak classification of cystic renal masses (2019)

Bosniak classification of cystic renal masses (2019)

The 2019 revision of the Bosniak classification, class by class — the defining imaging features, the reported malignancy risk, and what each class means for management.

Need the whole report too? Type a few findings and get it written ↓

Summary

ClassMalignancy riskManagement
Bosniak I~0% (benign)No follow-up required.
Bosniak II~0% (benign)No follow-up required.
Bosniak IIF~6%Follow-up imaging. CT or MRI at 6 months, 12 months, then annually for a total of 5 years if stable.
Bosniak III~55%Urology referral. Surgical or ablative management, or surveillance in selected patients.
Bosniak IV~90%Treat as renal cell carcinoma. Urology referral.
Get the whole report from a few sentences.

A sample dictation is ready below. Press generate, or type your own findings and end with “otherwise normal” to have the rest written out. No signup.

Now try it on your own case.

100 free reports over 14 days. No card, nothing to install.

Start your free trial →

Please leave out patient identifiers. Text is de-identified before the AI sees it and is not stored. Demo output is not for clinical use.

Class by class

Bosniak I

Bosniak I — malignancy risk ~0% (benign)
No follow-up required.

Defining features:

Bosniak II

Bosniak II — malignancy risk ~0% (benign)
No follow-up required.

Defining features:

Bosniak IIF

Bosniak IIF — malignancy risk ~6%
Follow-up imaging. CT or MRI at 6 months, 12 months, then annually for a total of 5 years if stable.

Defining features:

Bosniak III

Bosniak III — malignancy risk ~55%
Urology referral. Surgical or ablative management, or surveillance in selected patients.

Defining features:

Bosniak IV

Bosniak IV — malignancy risk ~90%
Treat as renal cell carcinoma. Urology referral.

Defining features:

Using the 2019 revision

Related

Source. Silverman SG, et al. Radiology 2019;292(2):475-488. View on PubMed

Frequently asked questions

Which Bosniak classes need follow-up or treatment?

Bosniak I and II cysts are benign (about 0% malignancy risk) and need no follow-up. Bosniak IIF (about 6% risk) gets surveillance imaging — CT or MRI at 6 months, 12 months, then annually for a total of five years if stable. Bosniak III (about 55% risk) goes to urology for surgical or ablative management or surveillance in selected patients. Bosniak IV (about 90% risk) is treated as renal cell carcinoma.

What imaging does the Bosniak 2019 classification require?

The 2019 revision applies only to cystic renal masses imaged with CT or MRI at renal mass protocol — it is not validated for ultrasound or for predominantly solid masses. Enhancement may be measured (an increase of 20 HU or more at CT, or 15% or more signal increase at MRI) or perceived qualitatively. Pseudoenhancement in small intrarenal cysts on CT is a recognized pitfall.

Why should a report state the Bosniak version used?

The 2019 revision reclassified several categories relative to the 2005 version and considerably narrowed class III, so the same lesion can carry different classes — and different management — under the two versions. Stating 'Bosniak IIF (2019 version)' makes the report unambiguous for the urologist and for later comparison. The 2019 system also added quantitative definitions, such as thin septa at 2 mm or less and thick at 4 mm or more.

This calculator, written into your report for you

MyRadAgent drafts the full report - and applies this guideline automatically, with the category and follow-up in the impression. Free trial runs in the browser: 100 reports over 14 days, no card, no IT ticket.

Try it on a report → or try it here first — no signup ↑
This is a reference implementation of a published guideline, for use by qualified clinicians. It does not account for patient-specific factors and is not a substitute for clinical judgment or a formal radiology consultation. See our full disclaimer.

BI-RADS, TI-RADS, LI-RADS, PI-RADS, O-RADS, Lung-RADS, CAD-RADS, NI-RADS and ACR are registered trademarks of the American College of Radiology. They are used here only to identify the published systems these tools implement; MyRadAgent is not affiliated with, sponsored by or endorsed by the ACR.